Point Biopharma

Point Biopharma Global Inc. is a radiopharmaceutical company based in Indianapolis, Indiana. It develops next-generation radioligand therapies for the treatment of cancer. Radioligand therapy enables the precise targeting of cancer by linking a radioisotope to a targeting molecule that delivers radiation directly to cancer cells, allowing significant anti-tumor efficacy while minimizing the impact on healthy tissue.

Point Biopharma's lead programs are in late-stage development. PNT2002 is a prostate-specific membrane antigen (PSMA) targeted radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC) patients after progression on hormonal treatment. top line data from the Phase 3 SPLASH study for PNT2002 is expected in the fourth quarter of 2023. PNT2003 is a somatostatin receptor (SSTR) targeted radioligand therapy for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Beyond the late-stage pipeline, Point Biopharma has several additional programs in earlier stages of development, including PNT2004 targeting fibroblast activation protein-alpha for solid tumors. The company operates an 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis and a research and development center in Toronto. These facilities, along with supply agreements, enable Point Biopharma to manufacture clinical and commercial radiopharmaceutical supply.

In December 2023, Eli Lilly and Company completed the acquisition of Point Biopharma for approximately USD 1.4 billion. The acquisition gives Lilly access to Point Biopharma's pipeline and specialized manufacturing capabilities in the radiopharmaceutical space.